• Process Performance Qualification (PPQ) Shortened by 50 Percent for Takeda’s New Prefilled Syringe Filling Line in Linz, Austria, for ENTYVIO® Subcutaneous (vedolizumab)
• Recognition Illustrates Takeda’s Patient-Centric Investment in Supply Flexibility and Demonstrates Build-up of Supply Chain Resilience
• Awarded Project Sets New Standard for PPQ for New Production Lines Helping to Shorten Time to Market

OSAKA, Japan and CAMBRIDGE, Massachusetts, April 16, 2024 - Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the category Operations with the 2024 Facility of the Year Awards (FOYA). The awarded project demonstrates Takeda’s continuous patient-focused process improvements in its manufacturing operations. The project was executed at Takeda’s manufacturing site in Linz, Austria, where Takeda managed to reduce the process performance qualification (PPQ) time by 50 percent for its prefilled syringe filling line for ENTYVIO Subcutaneous (SC) formulation. With this project, the foundation is laid to reduce PPQ timelines for new production lines while further improving supply chain resilience for the organization. The shorter PPQ time increases the flexibility to supply the markets with larger quantities in a shorter period of time.

“Projects like the one at our Linz site help us to respond in a much more flexible way to patients’ needs. At the same time, it helps our entire manufacturing network apply the learnings to future projects. This award reinforces our mission and the…